Refine Results
Sort By
From
To
Page 1
Page 1
Cancerimmunotherapies : Solid tumors and hematologic malignancies
Presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations.
Cancer drug resistance
In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic opportunities.
Cancer cell biology : methods and protocols
Provides detailed methods on the mechanisms of underlying cancer cell biology. Chapters guide readers through techniques for culturing cancer cell lines, xenografts, cryopreservation of tumor cells, analyzing the co-culture of breast cancer cells, protein secretion by ELISA, flow cytometry-based, multi-parametric immunofluorescence analysis, protein expression by western blot, analysis of surface protein levels, protein recycling by biotinylation assay, and proteomics analysis by liquid chromatography-mass spectrometry.
Cancer : Cell Structures, Carcinogens and Genomic Instability
Tumors can be induced by a variety of physical and chemical carcinogens. The resulting tumor cells are usually abnormal in their morphology and behavior and transmit their abnormalities to their daughter tumor cells. Most theories of the pathogenesis of tumors suggest that carcinogens in some way cause alterations either of the genomes or of inheritable patterns of gene expression in normal cells, which then cause morphological and behavioral changes. This volume presents a collection of articles aimed at the question by what genetic or epigenetic mechanisms carcinogens can cause morphological abnormalities of tumor cells. It includes reviews of cellular targets of known carcinogens, and presents varying viewpoints of how morphological abnormalities and the actions of carcinogens might be related.
Brain tumor pathology : Current diagnostic hotspots and pitfalls
Since Bailey and Cushing (1926), all brain tumor classifications have been called histogenetic. The nosographic position that the tumor types progressively acquired in the classification systems derived from the resemblance of tumor cells to those of the cytogenesis, modified whenever new information became available from different biological research fields and especially from molecular genetics. Classically, on the basis of the rough correspondence between the mature/immature aspect of tumor cells and the benign/malignant biological behavior of the tumors, the histological labels contained a prognostic significance. The supposed origin of the tumors was thus a factor for prognosis. Later on, with the concept of anaplasia (Cox, 1933; Kernohan et al., 1949) new criteria were introduced for establishing the malignancy grades of tumors. Immunohistochemistry and later molecular genetics further refined the prognostic diagnoses, substantially increasing the opportunities to recognize the cell origin of tumors, beside revealing the pathogenetic mechanisms. Prognoses became more accurate, as required by the greater and more targeted possibilities of therapy.
Analyzing T cell responses : How to analyze cellular immune responses against tumor associated antigens
Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer
Adaptive dynamic programming for chemotherapy drug delivery
Focuses on the practical application of Adaptive Dynamic Programming (ADP) in chemotherapy drug delivery, taking into account clinical variables and real-time data. ADP's ability to adapt to changing conditions and make optimal decisions in complex and uncertain situations makes it a valuable tool in addressing pressing challenges in healthcare and other fields. As optimization technology evolves, we can expect to see even more sophisticated and powerful solutions emerge.
